Origenis extends Research Alliance with Alcon to develop novel ophthalmic compounds
Origenis GmbH announced that it has extended the research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis´ compound design and synthesis capabilities with Alcon´s applied biology expertise, screening capabilities and development expertise.
Origenis has developed a unique process to design and synthesize novel molecules acting against different targets, which targets will be chosen by Alcon. Origenis will apply its technology platform MOREsystem® to deliver pre-clinical candidates with indication optimized profiles for certain Alcon targets.
Under the terms of the agreement, Alcon will retain the rights to any products for ophthalmic and nasal applications and Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.
Alcon will make research payments to Origenis through a series of development milestones and royalties on sales.
Dr. Michael Thormann, Managing Director at Origenis said: "This extension validates the strength of our technology platform, which allows the design, synthesis, and characterization of novel molecules acting against given targets in combination with giving these molecules indication-specific advantageous properties. Origenis´ approach combines lead finding and lead optimization in one step, thus, reducing attrition and shorting time to market."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
